Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucanix maintenance in advanced NSCLC
NCT00676507Phase 3Completed
- Sponsor
- NovaRx Corporation
- Start
- Jul 2008
- Primary completion
- Jan 2013
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Modified DNA Oligonucleotides
- Countries
- 8
01
Overview
A Phase 3 trial of belagenpumatucel-l in non-small cell lung cancer (NSCLC), sponsored by NovaRx Corporation. Started Jul 2008; status: completed.
02
Drugs
belagenpumatucel-l
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00676507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00676507.